Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis

NCT00869986 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00869986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00869986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis
Lead sponsor
Eli Lilly and Company
Phase
Phase 2/3
Overall status
Completed
Start date
November 30, 2006
Completion date
September 30, 2009
Enrollment
218 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis